Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.60 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621047 | 0.95 | KIF11 (0.56) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4620774 | 0.92 | KIF11 (0.60) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4621132 | 0.87 | KIF11 (0.55) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL14078149 | 0.87 | KIF11 (0.55) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4620637 | 0.85 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4620734 | 0.83 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4619541 | 0.83 | KIF11 (0.44) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL24202964 | 0.82 | KIF11 (0.71) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4620608 | 0.81 | KIF11 (0.57) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL4620255 | 0.81 | KIF11 (0.59) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | claimed |
| EP-1885702-A2 | QUINAZOLINONES | Merck Patent GmbH (DE) | 2008-02-13 | — | — | EP | claimed |
| WO-2006125555-A2 | QUINAZOLINONES | MERCK PATENT GMBH (DE) | 2006-11-30 | — | — | WO | claimed |
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234299-A1 | Quinazolinones | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234299-A1 | Quinazolinones | H1-3, NDUFS3, CCNT1 | KIF11 2324/4885MAP1LC3B 2831/4885CYP3A4 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.